Apixaban (Eliquis) is NOT appropriate as standard antithrombotic therapy for recent NSTEMI
For a patient with recent NSTEMI without atrial fibrillation, apixaban should NOT be used as part of the standard antithrombotic regimen. The evidence clearly demonstrates harm without benefit in this setting.
The Evidence Against Apixaban in NSTEMI
The APPRAISE-2 trial 1 definitively answered this question: adding apixaban 5 mg twice daily to standard antiplatelet therapy after acute coronary syndrome increased major bleeding events (hazard ratio 2.59) without reducing ischemic events (cardiovascular death, MI, or stroke). The trial was terminated early specifically because of this unfavorable risk-benefit profile. Notably, there were more intracranial and fatal bleeding events with apixaban.
Standard NSTEMI Antithrombotic Management
According to the 2014 AHA/ACC NSTEMI guidelines 2, the appropriate antithrombotic strategy consists of:
Acute phase:
- Aspirin (81-325 mg non-enteric coated initially, then 81 mg daily indefinitely)
- P2Y12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel for early invasive strategy)
- Anticoagulation with heparin/LMWH during hospitalization until PCI
Post-PCI:
- Dual antiplatelet therapy (DAPT) with aspirin plus P2Y12 inhibitor for at least 12 months
- No routine oral anticoagulation
The Critical Exception: Concurrent Atrial Fibrillation
If your patient has BOTH recent NSTEMI and atrial fibrillation requiring anticoagulation, then apixaban IS appropriate - but as part of a specific triple therapy regimen, not as monotherapy 3.
The AUGUSTUS trial 3 demonstrated that in AF patients with recent ACS/PCI:
- Apixaban was superior to warfarin (less bleeding: 10.5% vs 14.7%, fewer hospitalizations)
- Triple therapy should be minimized: Use apixaban + P2Y12 inhibitor + aspirin for only 1 week to 1 month maximum
- Then transition to dual therapy: Apixaban + clopidogrel (NOT ticagrelor/prasugrel due to bleeding risk) for up to 12 months
- Then apixaban monotherapy thereafter
Contemporary practice 4 supports this staged approach for AF patients post-NSTEMI.
FDA-Approved Indications for Apixaban
The FDA label 555 explicitly lists apixaban's approved uses:
- Stroke prevention in atrial fibrillation
- VTE prophylaxis after hip/knee replacement
- Treatment of DVT/PE
- Prevention of recurrent VTE
Notably absent: acute coronary syndrome or post-MI management without AF.
Common Pitfall to Avoid
Do not confuse the benefit of apixaban in AF patients (who happen to have ACS) with a benefit in ACS patients generally. The APPRAISE-2 trial 1 clearly showed that adding apixaban to antiplatelet therapy in high-risk ACS patients without an independent indication for anticoagulation causes net harm.